Red Tree Venture Capital is a West Coast-centric, early-stage life science venture capital firm that invests in breakthrough science emerging from premier academic and research institutions. The firm focuses on developing first-in-class or best-in-class therapeutics in oncology, neurology, and immunology, often providing the first institutional capital at seed, preclinical, or early clinical stages.
67% of their portfolio is in Biotech & Life Sciences. They made 1 investments in the last 12 months. Their most common stage is series-a (67% of deals). Average disclosed round size is $107.7M (across 3 rounds with reported amounts).
Portfolio
3
Fund Size
$272M
Top Stage
Series A
Last 12 Mo
1
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Excellergy, Inc. | Series A | $70M | Oct 2025 |
| CCARGO Therapeutics, Inc. | Series A | $200M | Mar 2023 |
 Ceribell, Inc. | Series C | $53M | Apr 2021 |
Top Co-Investors
Samsara BioCapital2 shared
Longitude Capital1 shared
The Rise Fund1 shared
RA Capital Management1 shared
Redmile Group1 shared
Wellington Management1 shared
Third Rock Ventures1 shared
Janus Henderson Investors1 shared
Ally Bridge Group1 shared
T. Rowe Price Associates, Inc.1 shared
Cormorant Asset Management1 shared
Emerson Collective1 shared
Last updated: 10 April 2026